CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$95.32
−1.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 47.0K | 167.0K | — | — | — |
| Gross Profit | (47.0K) | (167.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 136.7M | 145.0M | 104.2M | 60.6M | 35.3M |
| SG&A Expense | 72.0M | 27.2M | 9.1M | 5.6M | 4.4M |
| General & Admin Expense | 72.0M | 27.2M | 9.1M | 5.6M | 4.1M |
| Selling & Marketing Expense | — | — | — | — | 278.8K |
| Other Expenses | — | — | — | — | (278.8K) |
| Total Operating Expenses | 208.6M | 172.2M | 113.3M | 66.2M | 39.4M |
| Cost and Expenses | 208.7M | 172.2M | 113.3M | 66.2M | 39.4M |
| Operating Income (EBIT) | (208.7M) | (172.2M) | (113.3M) | (66.2M) | (39.4M) |
| Non-Operating | |||||
| Interest Income | 15.9M | 12.3M | 11.8M | 7.8M | 1.1M |
| Interest Expense | 35.0M | 17.1M | 10.3M | 5.3M | 2.1M |
| Net Interest Income | (19.1M) | (4.8M) | 1.5M | 2.5M | (978.9K) |
| Other Non-Op Income/Expense | (17.8M) | (4.8M) | 1.5M | 2.5M | (978.9K) |
| Non-Operating Income (excl Interest) | (23.3M) | (12.3M) | (11.8M) | (7.8M) | (1.1M) |
| EBT (Pre-Tax Income) | (226.5M) | (177.0M) | (111.8M) | (63.8M) | (40.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (226.5M) | (177.0M) | (111.8M) | (63.8M) | (40.4M) |
| Earnings from Cont. Ops | (226.5M) | (177.0M) | (111.8M) | (63.8M) | (40.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (226.5M) | (177.0M) | (111.8M) | (63.8M) | (40.6M) |
| Per Share | |||||
| Basic EPS | ($4.29) | ($3.78) | ($2.83) | ($2.69) | ($2.68) |
| Diluted EPS | ($4.29) | ($3.78) | ($2.83) | ($2.69) | ($2.68) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 54.8M | 52.5M | 39.4M | 23.7M | 15.4M |
| Diluted Shares Outstanding | 54.8M | 52.5M | 39.4M | 23.7M | 15.4M |
| Profitability Metrics | |||||
| EBITDA | (185.3M) | (159.7M) | (101.4M) | (58.3M) | (38.1M) |
| D&A | 137.0K | 167.0K | 129.9K | 142.8K | 210.9K |
| EBIT | (185.4M) | (159.9M) | (101.5M) | (58.5M) | (38.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026